VLRX - Valeritas Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.6500
+0.0700 (+4.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.5800
Open1.5800
Bid1.6100 x 1800
Ask1.6500 x 1300
Day's Range1.5008 - 1.6500
52 Week Range1.5008 - 33.2000
Volume589,245
Avg. Volume563,618
Market Cap11.81M
Beta (3Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)-14.5540
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Valeritas Announces Presentation of Preclinical h-Patch™ CBD Study at CannMed Conference

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today data from its preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion delivered via its h-Patch™ wearable drug delivery device have been accepted for a poster presentation at the annual CannMed Conference in Pasadena, CA, on September 23-24, 2019. Pharmacokinetic Study of Subcutaneous Infusion of Cannabinoid (CBD) Isolate in Dogs via the   h-Patch™ Wearable Device. On July 30th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device.

  • GlobeNewswire

    Valeritas Announces Poster Presentation of Preclinical h-Patch™ Apomorphine Study at the Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today a poster presentation at the Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia held in Rome, Italy, on October 14-16, 2019. On August 5th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of continuous subcutaneous infusion of apomorphine (Apo) delivered via its proprietary h-Patch™ wearable drug delivery device. The wearable h-Patch™ represents a patient-friendly subcutaneous delivery mechanism for Apo providing the benefits of a full 24-hour infusion of low dose Apo to eliminate “off” periods and improve motor status without tolerability issues seen with subcutaneous injections.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For September 13, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Sintx Technologies (NASDAQ: SINT ) shares ...

  • GlobeNewswire

    Valeritas Presents Positive CBD h-Patch™ Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today positive data from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion was presented at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston, Massachusetts. Data presented at the Summit showed rapid and robust absorption and distribution of 40mg CBD delivered over 24 hours with the h-Patch™ technology. “We are very excited by the data from this PK study and the potential our h-Patch™ technology has in providing peak plasma levels equivalent to oral administration despite delivering only a fraction of the amount of CBD,” said John Timberlake, President and Chief Executive Officer of Valeritas.

  • GNC Holdings Inks Retail Partnership Deal to Grow in Brazil
    Zacks

    GNC Holdings Inks Retail Partnership Deal to Grow in Brazil

    We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.

  • Innovation Aids Genomic Health, Merger Procedure on Track
    Zacks

    Innovation Aids Genomic Health, Merger Procedure on Track

    Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.

  • Insulet (PODD) Scales 52-Week High: What's Driving the Stock?
    Zacks

    Insulet (PODD) Scales 52-Week High: What's Driving the Stock?

    Insulet (PODD) has various favorable factors to maintain the current high.

  • GlobeNewswire

    Valeritas Announces Oral Presentation of Preclinical h-Patch™ CBD Study at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today an oral presentation to be given at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit held in Boston, MA, on September 10-12, 2019. On July 30th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device.

  • Thomson Reuters StreetEvents

    Edited Transcript of VLRX earnings conference call or presentation 8-Aug-19 8:30pm GMT

    Q2 2019 Valeritas Holdings Inc Earnings Call

  • GlobeNewswire

    Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that the Compensation Committee of Valeritas’ Board of Directors granted stock options to purchase an aggregate of 1,665 shares of Valeritas’ common stock to 4 newly-hired employees, with a grant date of August 28, 2019, pursuant to the Valeritas Holdings, Inc. 2018 Inducement Plan that was previously disclosed. The stock options were granted as inducements material to the new employees entering into employment with Valeritas in accordance with NASDAQ Listing Rule 5635(c)(4).

  • GlobeNewswire

    Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas’ V-Go® Meets Primary A1c Endpoint

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that a randomized controlled trial comparing the delivery of U-100 Regular Human Insulin (RHI) by V-Go versus delivery of Rapid Acting Insulin (RAI) by V-Go in patients with type 2 diabetes has met the primary A1c (blood sugar levels) endpoint.

  • Valeritas Holdings, Inc. (VLRX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Valeritas Holdings, Inc. (VLRX) Reports Q2 Loss, Tops Revenue Estimates

    Valeritas Holdings, Inc. (VLRX) delivered earnings and revenue surprises of 5.86% and 0.19%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Valeritas Announces Second Quarter 2019 Financial Results

    BRIDGEWATER, N.J., Aug. 08, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Allakos (NASDAQ: ALLK ) shares were up 112.6% ...

  • GlobeNewswire

    Preclinical Study Shows Valeritas Proprietary h-Patch™ Wearable Delivery Device an Effective Option for Continuous Infusion of Apomorphine

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today positive results from a preclinical pharmacokinetic (PK) study of apomorphine (Apo) subcutaneous infusion delivered via its h-Patch™ wearable drug delivery device. Valeritas’ h-Patch™ is a drug delivery technology that can facilitate the simple and effective subcutaneous delivery of injectable medicines to patients across a broad range of therapeutic areas.

  • Will Valeritas Holdings, Inc. (VLRX) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will Valeritas Holdings, Inc. (VLRX) Report Negative Earnings Next Week? What You Should Know

    Valeritas Holdings, Inc. (VLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Benzinga

    Valeritas Rallies On Positive Preclinical Data For CBD Delivery Using Wearable Device

    Valeritas Holdings Inc (NASDAQ: VLRX) shares have shed more than 61% in the year-to-date period. Valeritas, which makes the V-Go – Wearable Insulin Delivery Device using its proprietary h-Patch technology, announced positive results from a preclinical pharmacokinetic study of cannabidiol subcutaneous infusion with two dosing regimens delivered using its proprietary h-Patch wearable drug delivery device. The pharmacokinetics evaluated at time points up to 48 hours from the start of infusion showed that both dosages displayed rapid absorption and distribution with CBD levels in blood detected within an hour of the start of the infusion, Valeritas said.

  • GlobeNewswire

    Cannabidiol (CBD) Effectively Delivered Subcutaneously with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses their proprietary h-Patch™ technology, announced today positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device. The Company believes this study represents the first report of CBD delivered via subcutaneous infusion in any preclinical model.

  • Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas
    Zacks

    Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

    Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

  • Use Rising P/E Strategy to Buy 5 Winning Stocks
    Zacks

    Use Rising P/E Strategy to Buy 5 Winning Stocks

    Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.

  • GlobeNewswire

    Valeritas to Report Second Quarter 2019 Financial Results on August 8, 2019

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that it will release financial results for the second quarter of 2019 after the close of trading on Thursday, August 8, 2019. Valeritas’ management team will host a corresponding conference call beginning at 4:30 p.m. ET. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For July 11, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Vislink Technologies, Inc. (NASDAQ: VISL ) ...

  • GlobeNewswire

    Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Economic Advantages Compared to Multiple Daily Injection Therapy for Insulin Dependent Type 2 Diabetes Population

    BRIDGEWATER, N.J., July 08, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, announced.

  • GlobeNewswire

    Valeritas Files Special 510(k) with FDA for Labeling Change to Include the Use of Regular Human Insulin In V-Go® Wearable Insulin Delivery Device

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced it has filed a “Special 510(k): Device Modification” submission with the FDA  that includes using regular human insulin (RHI) in the device. A small peer-reviewed study published in Clinical Diabetes in October 2016 concluded that use of RHI administered by V-Go resulted in improved glycemic control with an estimated annual direct pharmacy costs savings exceeding $3,000 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070587/). “Valeritas is focused on solutions that are both highly effective and help patients reduce their costs in managing diabetes.

  • GlobeNewswire

    Valeritas Announces Milestone of 20 Million V-Go® Insulin Delivery Devices Sold

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, announced today it has surpassed a significant milestone of selling more than 20 million V-Go insulin delivery devices in the United States. “There are millions of patients with type 2 diabetes on insulin therapy in the United States, and the majority are not meeting their A1c or blood sugar goal,” said John Timberlake, President and Chief Executive Officer of Valeritas. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.